FDA’s Approval Of A New Alzheimer’s Drug Shows What’s Wrong With The Way We Care For Frail Older Adults Medicare will spend tens of billions on a new Alzheimer's drug of limited benefit but policymakers resist when asked to spend far less on more modest, but practical, functional supports to help families care for frail older adults and younger people with disabilities.